Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Summit Therapeutics: Market Overreaction Creates Opportunity
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buying opportunity for long-term investors.
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
Is SMMT Stock A Buy After Its Recent Plunge?
Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past year, driven by favorable updates regarding its lung cancer medication, ivonescimab.
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistically significant manner puts doubt on company's ability to file a BLA of ivonescimab for the treatment of patients with EGFR 2nd-line NSCLC. The global non-small cell lung cancer therapeutics market is expected to reach $37.49 billion by 2035.
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 44.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in the PD-1/VEGF bispecific antibody space, with major players like Merck and BioNTech entering the market. Summit's financial health shows a significant cash runway into late 2027, despite high R&D and G&A expenses and no revenue generation.
